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Fig 1. A, Drug reaction. Linear and reticulated areas of hyperpigmentation on the abdomen.
B, Drug reaction. Hematoxylin and eosin section showing a mildly atrophic epidermis with
focal basal vacuolar change. There is dysmaturation of the keratinocytes likely related
to chemotherapy effect. Melanin is present within the stratum corneum. Within the dermis a
scant infiltrate of lymphocytes surround the superficial vessels and there are scattered
melanophages.
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patient, a similar eruption has been described previ-
ously in association with cyclophosphamide and
5-fluorouracil.2,3 The comparable mechanism of ac-
tion of ifosfamide compared with cyclophospha-
mide may have resulted in a similar eruption.2
However, the cyclophosphamide pigmentation re-
ported was more patchy and coarse than seen in our
patient. A potential mechanism resulting in this
peculiar pattern of hyperpigmentation may be local
vascular inflammation and subsequent postinflam-
matory pigmentary alteration. Although minor pru-
ritus was associated with the eruption, the pattern of
skin changes did not correspond to those areas that
weremost itchy. The patient was also on other drugs,
but they had been used for an extended time and
have not been reported to result in similar cutaneous
changes.
We suspect the cutaneous eruption was due to the
combination of methotrexate, ifosfamide, and eto-
poside. It appears most temporally related to meth-
otrexate, although this is not conclusive of causality.
Our patient received another round of chemo-
therapy 1 month later without further exacerbation.
The anti-inflammatory effect from the continued use
of triamcinolone cream may have prevented recur-
rence. Interestingly, a report describing a similar
hyperpigmented pattern following treatment with
5-fluorouracil also described lack of recurrence
despite continued use of the causative drug at the
same dosage.3 Our case resolved with intermediate-
strength topical steroid treatment, which should
provide reassurance and prevent unnecessary bi-
opsies in patients who present with similar findings.
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Occurrence of psoriatic plaques on previous
adalimumab injection sites during disease
relapse in a patient with pustular psoriasis
To the Editor: Psoriasis has been reported after tumor
necrosis factor (TNF) inhibitor treatment in patients
with rheumatic diseases.1 Recently, we observed a
patient with pustular psoriasis in whom psoriatic
plaques developed on previous adalimumab injec-
tion sites during disease relapse.
This 45-year-old man suffered from severe acro-
dermatitis continua for 25 years and had initially
Fig 1. Psoriasis. Two well-defined scaly plaques on the
abdomen.
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Letters e25presented with subungual pustules and a few scaly
plaques on the back. The following year, he
experienced 3 episodes of generalized pustules
and fever. Afterward, his psoriasis remained
confined to the digits, left hand, forearm, legs, and
skin folds. He had been treated with oral etretinate
(later acitretin) for 20 years and had received other
systemic and topical agents, including ustekinumab
and systemic corticosteroids, with limited benefit.
Adalimumab was initiated 5 years ago, and his
condition improved, but treatment was discontin-
ued after 2 years for financial reasons. Acitretin was
discontinued months later due to hyperlipidemia,
and his psoriasis eventually flared. Pustules recurred
on his legs and left palm, and thin plaques on the
left forearm were studded with tiny pustules. Two
isolated psoriatic plaques developed in abdominal
skin where adalimumab had been injected previ-
ously (Fig 1). No typical psoriatic plaques occurred
elsewhere. Although he had generalized pustular
psoriasis 18 years earlier, he had not suffered from
typical psoriatic plaques in this area. After the
reintroduction of adalimumab and acitretin treat-
ment, the psoriatic plaques on his abdomen
resolved completely.
Psoriasiform dermatosis developing after TNF
inhibitor treatment could present as de novo
psoriasis, an exacerbation of previous psoriasis,
or a phenotype switch of psoriasis. The paradox-
ical development of psoriasis is suggested to be
due to the production of unopposed interferon-
alpha by plasmacytoid dendritic cells and the
disruption of the cytokine milieu.2 However, the
appearance of typical psoriatic plaques on previ-
ously uninvolved skin during disease relapse on
previous adalimumab injection sites has not been
reported.
Although the exact pathogenesis is unknown, it is
clear that TNF blockers are effective in the treatment
of psoriasis, while TNF is also a potent anti-
inflammatory cytokine.2 We speculate that the keycytokine in pustular psoriasis may be different from
plaque type psoriasis (IL-36 versus IL-17).3,4 A
6-month remission duration usually exists after
adalimumab treatment.5 It is likely that the residual
effects of adalimumab set the previous injection sites
more vulnerable to the effect of the early initiating
cytokines (IL-36) of pustular psoriasis. However,
because TNF is important in the maintenance of
the plaque lesions that formed subsequently, the
patient’s psoriasis responded again to adalimumab
treatment. Koebner phenomenon from repeated
injections is another possibility. However, it is less
likely because the size of the psoriatic plaques
exceeded far beyond the injection points, and the
patient did not observe psoriatic lesions on other
areas of his recent trauma.
In conclusion, we reported the occurrence of
psoriatic lesions on previously unaffected adalimu-
mab injection sites during disease relapse. The exact
mechanism awaits further investigation.
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pigmentosus
To the Editor: Frontal fibrosing alopecia (FFA) is a
lymphocyte-mediated primary cicatricial alopecia
predominantly affecting the frontal hairline and
eyebrows. FFA shares common histopathologic
features with other lymphocyte-mediated cicatricial
alopecias such as lichen planopilaris (LPP), central
centrifugal alopecia, and pseudopelade (Brocq),
which are only distinguishable clinically.1 LPP has
been associated with mucocutaneous lichen pla-
nus (LP); however, the patterns of LP associated
with other lymphocyte-mediated cicatricial alope-
cias are less well established. Cases of coexistent
oral or cutaneous LP and FFA have been
observed.2,3 Recently, a case series of patients
from South Africa with coexisting FFA and lichen
planus pigmentosus (LPPigm) was published, in
addition to a case report from India with similar
findings.4,5
We report 2 Hispanic women with FFA and
LPPigm (Table I). Both women presented for
evaluation of progressive gray-brown macules on
the face and neck in a photodistribution (Fig 1, A).
Patient 1 secondarily complained of frontotemporal
hair loss. Patient 2 noted complete eyebrow loss over
the past several years; she was not aware of the
subtle frontotemporal recession noted on exam. In
both cases, the onset of LPPigmwas perimenopausal
and preceded the onset of FFA. Biopsy from
the neck of patient 1 revealed atrophic vacuolar
interface reaction with postinflammatory pigmentary
alteration, consistent with LPPigm (Fig 1, B); a
temple biopsy revealed lymphocyte-mediated
cicatricial alopecia (Fig 1, C ). For patient 2,
biopsy from the neck revealed atrophic lichenoid
interface reaction and another from the frontal
scalp revealed lymphocyte-mediated cicatricial






LPPigm and FFA (months)
Patient 1 54 56 24
Patient 2 51 49 12The case series by Dlova4 is remarkable for the
strong association of FFA with LPPigm, with more
than 50% of the patients with FFA having LPPigm.
The association of FFA with LPPigm further supports
a shared underlying mechanism between LP and the
primary lymphocytic alopecias. In our cases and
those in the series by Dlova, the LPPigm preceded
the onset of FFA, often by several months to years.4 It
has been suggested that clinical and histopathologic
evidence of FFA should be sought in patients with
LPPigm.4 Early recognition of FFA is important to
permit treatment with the intention of slowing
if not preventing progression. We encourage derma-
tologists to examine their patients with LPP for FFA
and to examine their patients with FFA for LLP,
because this association seems not uncommon in
certain ethnicities.
The role of ethnicity in LP and primary
lymphocytic cicatricial alopecias needs to be
further elucidated. LPPigm has been documented
predominantly in dark-skinned patients. While
ethnicity is variably included in reports of FFA, the
majority describe Caucasian patients. The patients
reported by Dlova4 and by Rao et al5 were
dark-skinned of African and Indian ethnicities.
The Hispanic women described herein provide
additional examples of FFA in dark-skinned patients
and further supports an association with LPPigm. We
hypothesize that in patients with FFA, the variant of
LP that is associated is that which is most commonly
seen in their given ethnicity. We recommend
noting ethnicity in future studies of LP and its various
expressions, as well as in studies of the lymphocyte-
mediated primary cicatricial alopecias.
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